Introduction
Protein 4.1 of red blood cells (4.1R) is a multifunctional protein essential for maintaining erythrocyte shape and membrane mechanical properties, such as deformability and stability, through lateral interactions with spectrin and actin in the skeletal network and vertical interactions with cytoplasmic domains of transmembrane proteins, glycophorin C, and band 3 (Takakuwa 2000) . The protein 4.1 family comprises a group of skeletal proteins that mainly includes 4.1R, 4.1G (general type), 4.1B (brain type), and 4.1N (neuron type). The proteins are structurally related to erythroid membrane skeletal protein 4.1R, which plays a critical role in determining the morphology and mechanical stability of the red blood cell plasma membrane. 4.1 proteins are characterized by the presence of three main conserved structural and functional domains. The FERM domain (F, 4.1; E, ezrin; R, radixin; M, moesin) (Chishti et al. 1998 ), a 30-kDa N-terminal membrane-binding domain, possesses binding sites for the cytoplasmic tails of integral membrane proteins such as band 3 (Pasternack et al. 1985; Lombardo et al. 1992 ), glycophorin C (Marfatia et al. 1995) , CD44 (Nunomura et al. 1997) , and Drosophila neurexin (Ward et al. 1998) . The FERM domain also binds to p55 (Marfatia et al. 1995) and calmodulin (Tanaka et al. 1991) , the latter interaction being important for regulating the affinity of 4.1R-band 3 and 4.1R-CD44 interactions (Nunomura et al. 1997 ). An internal 8-to 10-kDa domain contains the critical spectrin-actin binding activity required for membrane stability (Schischmanoff et al. 1995) , and the C-terminal 22-to 24-kDa domain has been reported to bind the immunophilin FKBP13 (Walensky et al. 1998) and NuMA (Mattagajasingh et al. 1999) .
Materials and methods
A cDNA library was constructed with a modified pBluescrip II SK (ϩ) vector by using 18-week-old human Abstract Protein 4.1 is an important structural protein that is expressed in erythroid and in a variety of nonerythroid tissues. In mammalian erythrocytes, it plays a key role in regulating the physical properties of mechanical stability and deformability in membranes by stabilizing the spectrinactin interaction. The protein 4.1 family mainly comprises 4.1R, 4.1G (general type), 4.1B (brain type), and 4.1N (neuron type). We identified a novel human 4.1 (4.1O) gene that is 2312 bp in length and encodes a protein of 553 amino acid residues. The protein shared homology with mouse protein 4.1B (identity 38%, similarity 55%) with a FERM domain. The expression pattern of the human 4.1O gene in 16 tissues showed that there was a transcript only in ovary, whereas in the remaining 15 tissues, specific bands of the transcript could not be detected. In eight human fetal tissues, the specific bands of the transcript could be detected in skeletal muscle, with lower levels detected in thymus and brain. The 4.1O gene consists of 14 exons and 13 introns and was mapped to Chromosome 9q21-9q22 by bioinformatics analysis. primer. An M13Rev primer and synthetic internal walking primers were designed according to the obtained cDNA sequence fragments. Each part of the inset was sequenced at least three times bidirectionally. Subsequent editing and assembly of all the sequences from one clone was performed using Acembly (Sanger Centre Cambs, UK).
Key words Protein 4.1O · MTC panel PCR · Chromosome 9q21-9q22 · Ovary · Tumor

Results
From our large-scale sequencing analysis of human cDNA libraries, we cloned a full-length cDNA of the human 4.1O gene, encoding a homologue of the mouse 4.1B gene and the human 4.1B gene. The nucleotide sequence has been submitted to the Genbank/EMBL database with accession number AY137774. The cDNA consists of 2312 bp and contains an open reading frame (ORF) of 1662 bp encoding a protein of 553 amino acids. Using domain analysis on the web service of the National center for Biotechnology Information (NCBI; RPS-BLAST), the FERM domain was found to be located at residues 6-181 (91.6% aligned) of the protein sequence. The cDNA is considered to be full length because there is an upstream in-frame stop codon (TAG) and polyA signals (AATAAA) after the ORF (Fig. 1A) . Bioinformatics analysis using BLASTx revealed that 4.1O shared homology with AK094281 protein (93% identity and 93% similarity), mouse 4.1B (m4.1B, mDAL-1, 38% identity and 55% similarity), and human 4.1B (h4.1B, hDAL-1, 38% identity and 56% similarity). The predicted protein AK094281, which is mapped to chromosome 9, has 460 amino acids. Because of the difference in the N-terminal and C-terminal amino acid sequence, and no upstream inframe stop codon, it may not be considered full length and is likely to be a splicing variant of 4.1O. Various levels of homology with the FERM domain of AK094281 protein, 4.1G, 4.1N, and 4.1R were also detected (Fig. 1B) .
To determine the chromosomal localization of the human protein 4.1O gene, we used the international human genome database on NCBI. The gene was mapped to contig NT-023935.11, spanning 220 364 bp. The contig was located at 9q21-9q22, whereas 4.1R, 4.1N, 4.1G, and 4.1B were located at 1pter-p34, 20q11.2-q12, 6q23, and 18p11.32. Comparing our cDNA with the genome sequence of 4.1O suggested that the gene consisted of 14 exons and 13 introns. All sequences at the exon-intron junctions were consistent with the AG-GT rule (Table 1) .
The tissue distribution of protein 4.1O was determined by two human multiple tissue cDNA (MTC) panels, a human fetal panel, and a human tumor panel (Clontech, Palo Alto, CA, USA), which were used as PCR templates according to the manufacturer's protocol. The sequences for human 4.1O specific primer pairs were 5Ј-CTGGCTTG AACCTAACAAGTCCATCT-3Ј (4.1O F, from 241 to 266 bp) and 5Ј-CAGGCAGCTGGTGTTGAAGTATGG AAT-3Ј (4.1O R, from 841 to 866 bp). Thirty-six cycles of amplification (30 s at 94°C, 30 s at 60°C, and 1 m in at 72°C) were performed using ELONGASE DNA polymerase (GIBCO BRL, Gaithersburg, MD, USA). The PCR product of 4.1O was then resolved on a 1.5% metaphor agarose gel (FMC, Philadelphia, PA, USA). In total, 16 human tissues were tested (Fig. 2A) . Our data revealed a transcript only in ovary, whereas in the remaining 15 tissues, specific bands of the transcript could not be detected. For this focal expression, we termed AY137774 4.1O (ovary type). In eight human fetal tissues, we found a transcript in skeletal muscle, with lower levels in thymus and brain (Fig. 2B) . Additionally, in the human tumor panel we found that, in colon adenocarcinoma CX-1, colon adenocarcinoma GI-112, lung carcinoma GI-117, lung carcinoma LX-1, prostatic adenocarcinoma PC3, ovarian carcinoma GI-102, breast carcinoma GI-101, and pancreatic adenocarcinoma GI-103, specific bands of the transcript could not be detected (data not shown).
Discussion
Earlier studies show that the protein 4.1B gene, DAL-1 (differentially expressed in adenocarcinoma of the lung), is lost in approximately 60% of non-small cell lung carcinomas, and exhibits growth-suppressing properties in lung cancer cell lines. When DAL-1 was reintroduced into nonexpressing non-small cell lung carcinoma cell lines, it was shown to suppress growth. In addition, significantly reduced expression (Ͼ50%) of DAL-1 was measured in 39 primary non-small cell lung carcinoma tumors as compared with patient-matched normal lung tissue. DAL-1 is thought to be a membrane-associated protein with the potential to play an important role in the origin and progression of lung cancer (Tran et al. 1999 ). In addition, by using loss of heterozygosity, reverse transcriptase-PCR, Western blot, and immunohistochemistry analyses, Gutmann et al. (2000) found DAL-1 loss in 60% of sporadic meningiomas. Analogous to merlin, DAL-1 loss is an early event in meningioma tumorigenesis that suggests these two protein 4.1 family members are critical growth regulators in the pathogenesis of meningiomas. Furthermore, DAL-1 suppresses cell proliferation in meningioma, but not in schwannoma cells. Similar to merlin, DAL-1 interacts with other ERM proteins and betaII-spectrin, but not the merlin interactor Identity is indicated by a black box, and similarity is indicated by a gray box Fig. 1 . Continued protein, SCHIP-1. These observations suggest that the two protein 4.1 meningioma tumor suppressors, merlin and DAL-1, may be functionally distinct proteins with different mechanisms of action (Gutmann et al. 2001) .
We report here a novel human band 4.1 (4.1O) gene, which, by bioinformatics analysis from NCBI, is found to be located at chromosome 9q21-9q22, whereas 4.1R, 4.1N, 4.1G, and 4. 1B are located at a different chromosome. 4.1O is 2312 bp in length and encodes a protein of 553 amino acid residues in which the 4.1 family domain (FERM) is identified. By BLASTx at NCBI, we found that the predicted protein shares homology with mouse 4.1B (38% identity and 55% similarity) and human 4.1B (37% identity and 55% similarity). In the cerebellum, 4.1O expresses in skeletal muscle, with lower levels in thymus and brain. Northern blot analysis showed that 4.1B was expressed in brain, placenta, kidney, heart, lung, pancreas, and skeletal muscle (Parra et al. 2000) . Interestingly, the expression pattern of the human 4.1O gene in 16 tissues reveals a transcript only in ovary, which is different from that of 4.1B. Because 4.1B was considered a protein 4.1 tumor suppressor, we also checked 4.1O in a human tumor panel. Interestingly, no specific band of the transcript could be detected, particularly in ovarian carcinoma GI-102. Our data reveal that there is a transcript in normal ovary but not in ovarian carcinoma GI-102. This result indicates that 4.1O may be associated with ovary tumor. Future studies will focus on the expression and function of the 4.1O protein, and the role of human 4.1O.
